 As COMPASS Pathways NASDAQ: CMPS crunches more data from a recent trial investigating psilocybin therapy for treatment-resistant depression TRD, findings show that a higher dose of 25mg compared to 1mg and 10mg occasioned an increase in positive feelings of interest in life and a decrease in negative feelings of distress and fear. COMPASS phase IIb clinical trial results are a product of the companys focus since 2018 when it received FDA breakthrough therapy designation for its COMP360 psilocybin treatments for TRD. 